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Introduction
For decades, essential hypertension has been primarily
viewed from a hemodynamic, neural, and renal perspective.
However, based on mounting evidence from clinical, epi-
demiological, and experimental studies, it has become
increasingly recognized that disturbances in carbohydrate
and lipid metabolism often accompany high blood pres-
sure, and that essential hypertension may also represent a
disorder of cardiovascular endocrinology and metabolism
(1, 2). In patients with essential hypertension, clustering of
metabolic cardiovascular risk factors — including glucose
intolerance, hyperinsulinemia, and hypertriglyceridemia —
may promote susceptibility to target organ damage and
partly explain why conventional antihypertensive agents
have failed to reduce the risk for coronary heart disease to
the extent predicted from epidemiological studies (2).
Recently, a provocative hypothesis has emerged in which
inherited disorders of carbohydrate or lipid metabolism
are held to be at the core of the hypertension syndrome and
to contribute to the primary pathogenesis of increased
blood pressure. Studies in nonobese subjects with a fami-
ly history of hypertension and in a variety of experimental
animal models have suggested that alterations in carbohy-
drate and/or lipid metabolism can influence the regulation
of blood pressure and might precede the development of
hypertension (3–5). The lack of insulin resistance in
patients with secondary forms of hypertension, together
with observations of disordered carbohydrate and lipid
metabolism in cultured adipocytes from hypertensive ani-
mals, indicates that at least some endocrine-metabolic dis-
turbances are not simply a consequence of increased blood
pressure (4, 6–8). Hence, there is intense interest in identi-
fying genetic mechanisms that may underlie the associa-
tion between increased blood pressure and other cardio-
vascular risk factors in essential hypertension.
The spontaneously hypertensive rat (SHR) is the most
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Disorders of carbohydrate and lipid metabolism have been reported to cluster in patients with essential hyper-
tension and in spontaneously hypertensive rats (SHRs). A deletion in the Cd36 gene on chromosome 4 has
recently been implicated in defective carbohydrate and lipid metabolism in isolated adipocytes from SHRs.
However, the role of Cd36 and chromosome 4 in the control of blood pressure and systemic cardiovascular
risk factors in SHRs is unknown. In the SHR.BN-Il6/Npy congenic strain, we have found that transfer of a seg-
ment of chromosome 4 (including Cd36) from the Brown Norway (BN) rat onto the SHR background induces
reductions in blood pressure and ameliorates dietary-induced glucose intolerance, hyperinsulinemia, and
hypertriglyceridemia. These results demonstrate that a single chromosome region can influence a broad spec-
trum of cardiovascular risk factors involved in the hypertension metabolic syndrome. However, analysis of
Cd36 genotypes in the SHR and stroke-prone SHR strains indicates that the deletion variant of Cd36 was not
critical to the initial selection for hypertension in the SHR model. Thus, the ability of chromosome 4 to influ-
ence multiple cardiovascular risk factors, including hypertension, may depend on linkage of Cd36 to other
genes trapped within the differential segment of the SHR.BN-Il6/Npy strain.
J. Clin. Invest. 103:1651–1657 (1999).
widely studied model of essential hypertension and has
been reported to exhibit a number of abnormalities in car-
bohydrate and lipid metabolism (4, 5, 7, 9–11). As with
studies of other complex traits, the ability to detect disor-
dered carbohydrate or lipid metabolism in the SHR will
depend on the type of normotensive control strain used for
comparison, the techniques used to assess the phenotypes
of interest, and the environmental and dietary circum-
stances of the study (5, 11, 12). Under the appropriate
experimental conditions, systemic and cellular defects in
both carbohydrate and lipid metabolism can be clearly
demonstrated in the SHR. Thus, given proper under-
standing of key study variables that influence these meta-
bolic phenotypes, the SHR can provide a useful tool for
investigating the clustering of cardiovascular risk factors
in spontaneous hypertension.
In the SHR, a significant advance has recently been
made in understanding the molecular basis for disordered
carbohydrate and lipid metabolism that could shed light
on the clustering of systemic cardiovascular risk factors in
essential hypertension. Aitman et al. (13) have identified
a deletion in the SHR gene for Cd36 that encodes a fatty
acid receptor/transporter involved in the transmembrane
transport of long-chain fatty acids in adipose tissue and
in cardiac and skeletal muscle. The SHR carries a deletion
variant of Cd36 that results in the near-complete lack of
expression of normal Cd36 protein in adipocyte plasma
membranes (13). Cd36 maps to the telomeric region of rat
chromosome 4 that includes peak areas of linkage to SHR
defects in insulin-stimulated glucose transport and cate-
cholamine-mediated lipolysis in isolated adipocytes (8,
13). To confirm these linkage studies directly, we devel-
oped a congenic strain in which the deletion variant of
Cd36 in the SHR was replaced with a wild-type variant
from the normotensive Brown Norway (BN) rat. Transfer
of the Cd36 gene from the normotensive BN rat onto the
genetic background of this SHR congenic strain was asso-
ciated with significant increases in both insulin-stimulat-
ed glucose transport and catecholamine-mediated lipoly-
sis in isolated adipocytes (13). These findings, together
with results of metabolic studies in transgenic mice that
overexpress Cd36, have provided compelling evidence that
at least in isolated adipocytes, the SHR deletion in Cd36
is a major genetic determinant of disordered carbohydrate
and lipid metabolism (8, 13).
Based on the foregoing observations, a key question that
now arises is whether the region of chromosome 4 that
contains Cd36 is also involved in the genetic control of
blood pressure and the systemic cardiovascular risk factors
that tend to cluster in essential hypertension — namely,
impaired glucose tolerance, hyperinsulinemia, and hyper-
triglyceridemia. Accordingly, we investigated whether
replacing this segment of chromosome 4 in the SHR with
the corresponding chromosome region from the nor-
motensive BN rat would improve blood pressure, systemic
glucose tolerance, serum insulin levels, and serum triglyc-
erides. We have also genotyped multiple strains of SHR to
investigate the relationship of the Cd36 deletion variant to
the genealogy of hypertension in this model.
Methods
Strain derivation and genetic characterization. We measured blood
pressure and systemic metabolic risk factors in the same SHR
progenitor and congenic strains used to investigate the rela-
tionship of Cd36 to SHR defects in adipocyte insulin sensitivi-
ty and lipolysis (13). The SHR progenitor and congenic strains
were derived from a progenitor strain of SHR (SHR/Ola) that
descends from inbred SHR originally obtained from the
National Institutes of Health (Bethesda, Maryland, USA). This
progenitor strain of SHR has been maintained by brother · sis-
ter mating in Prague for more than 15 years and was beyond the
F90 generation when congenic breeding was initiated. The
SHR-chromosome 4 congenic strain was derived by transfer-
ring a segment of chromosome 4 from an inbred BN strain
(Charles River Laboratories, Kingston, New York, USA) onto
the genetic background of the SHR/Ola strain. In previous link-
age studies in the SHR, putative quantitative trait loci (QTLs)
for increased blood pressure and disordered carbohydrate and
lipid metabolism were mapped to relatively broad regions of
chromosome 4 (8, 14–16). Accordingly, in deriving the current
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Figure 1
Linkage map of chromosome 4. Linkage map showing the transferred
segment of chromosome 4 in the SHR.BN-Il6/Npy congenic strain. The
filled bar denotes the chromosome region from the BN strain that has
been fixed in the homozygous state on the SHR background. The cross-
hatched bar denotes region in which some residual heterozygosity may
exist within the congenic strain. The open region denotes the flanking seg-
ment of SHR chromosome. Map distances are adapted from chromo-
some 4 maps of the WIBR/MIT Rat Genome Center (17), Jacob et al.
(30), and Pravenec et al. (31). The position of Cd36 is based on radia-
tion hybrid mapping results of Aitman et al. (13).
congenic strain, we selected a large piece of chromosome 4 to
increase the chance of capturing the QTL in the transferred
chromosome segment. The markers Il6 and Npy were used for
selection of heterozygous carriers in each backcross generation.
After 8 generations of selective backcrossing to the SHR pro-
genitor strain, the differential segment was fixed by intercross-
ing heterozygotes and selecting for offspring inheriting the
homozygous BN Il6-Npy chromosome segment. The size of the
differential segment was estimated by genotyping of
microsatellite markers on chromosome 4 (17). The congenic
status of the strain was confirmed by analysis of more than 60
widely dispersed microsatellite markers on other chromo-
somes. The official designation of this congenic strain is
SHR.BN-Il6/Npy. For purposes of simplicity, however, we refer
to it as the SHR-chr.4 congenic strain. Animals of the N8F3 or
greater generation were used in the current studies. Cd36 geno-
typing was also performed in SHRs obtained from Charles
River Laboratories, Taconic Farms (Germantown, New York,
USA), the Czech Academy of Sciences, and from a stroke-prone
strain of SHR obtained from the colony maintained at the Uni-
versity of Michigan.
Cd36 genotyping. The SHR deletion variant in Cd36 was detect-
ed by Southern blot analysis of PstI-digested genomic DNA
probed with a DNA fragment that hybridizes to exon 6 of the
published sequence for Cd36 (GenBank accession no. L19658).
The probe was prepared by PCR amplification of exon 6 of
Cd36 using the following primers: upstream 5¢ -TCA AGG TGT
GCT CAA CAG CC-3 ¢ ; downstream 5 ¢ -AGG ATA AAA CAC
ACC AAC TGT-3 ¢ . This probe-enzyme combination detects
both the normally transcribed wild-type copy of Cd36 and a
duplicated nontranscribed version of Cd36 present in a variety
of normotensive rat strains tested to date (WKY, BN, Lewis,
Dahl R). Southern blot analysis of SHR genomic DNA shows
missing bands caused by deletion of the normally transcribed
copy of Cd36 (13). We also performed PCR analysis of the HinfI
RFLP that distinguishes the SHR deletion variant in Cd36
described previously by Aitman et al. (13).
Hemodynamic studies. Arterial blood pressures and heart rates
were measured continuously in unanesthetized, unrestrained
male SHR progenitor rats and SHR-chr.4 congenic rats between
10 and 14 weeks of age, using radiotelemetry. All rats were
allowed to recover for at least 10 days after implantation of
radiotelemetry transducers before the blood pressure recordings
were started. Pulsatile pressures and heart rates were recorded
in 5-second bursts every 5 minutes during the day (0600 to 1800
hours) and during the night (1800 to 0600 hours) for 4 weeks.
From these data, individual weekly means for daytime and
nighttime blood pressures and heart rates were calculated for
each rat in each week of the study. The results from the rats were
then averaged to obtained group means. Rats were fed standard
laboratory chow and tap water ad libitum throughout the study.
Assessment of metabolic cardiovascular risk factors. We tested for
the presence of hyperglycemia, hyperinsulinemia, and dyslipi-
demia in 8- to 10-week-old male SHR progenitor and congenic
rats under 2 different dietary conditions. Baseline blood sam-
ples were obtained via tail vein between 0900 and 1200 hours
in nonfasted rats maintained on standard laboratory chow. The
animals were then given a high-fructose diet (60% fructose) for
15 days, and the blood sampling was
repeated. Administration of a high-
fructose diet is a well-known method
for provoking insulin resistance, and
enabled us to test for possible envi-
ronment-genotype interaction in the
regulation of risk factor clustering in
the SHR model. An intraperitoneal
glucose tolerance test was performed
on day 13 of fructose feeding. The
fructose diet was taken away from the rats in the morning; 7
hours later, the rats were intraperitoneally injected with a 15%
glucose solution (1 mL/100 g body weight, or 1.5 g/kg). Blood
was taken from the tail without anesthesia before the glucose
injection and then 30, 60, and 120 minutes after the injection.
Blood samples were obtained and immediately centrifuged at
4°C, and the serum was stored frozen at –70°C until analysis.
Glucose was measured by the glucose oxidase technique; rat
insulin was measured by radioimmunoassay (Amersham Life
Sciences Inc., Arlington Heights, Illinois, USA); and total cho-
lesterol, triglycerides (without glycerol blanking), HDL choles-
terol, and nonesterified fatty acids were measured using stan-
dard enzymatic techniques (14, 18, 19).
Statistical analysis. All data are expressed as mean – SEM. Day-
time and nighttime blood pressures, heart rates, and body weights
over the course of the study were separately analyzed by repeated
measures ANOVA. Individual means for blood pressures, body
weights, and serum levels of glucose, insulin, and lipids were com-
pared by t test. Statistical significance was defined as P < 0.05.
Results
Genotyping results. Genotype results obtained with more
than 60 widely dispersed polymorphic microsatellite
markers confirmed that the SHR progenitor strain and
the SHR-chr.4 congenic strain were genetically identical
except for the differential segment of chromosome 4
transferred from the BN donor strain. The size of the
transferred BN chromosome segment is approximately
37 cM, as defined by testing with the following chromo-
some 4 markers (Figure 1): D4Rat247, Il6, D4Rat142,
D4Rat139, D4Rat1, D4Rat149, D4Mgh2, D4Rat26,
D4Rat33, D4Rat169, D4Rat108, and D4Rat34. Map-
ping studies in recombinant inbred strains, and the
results of radiation hybrid analysis, have shown that the
Cd36 gene is located near Il6 at the telomere of chromo-
some 4 (Figure 1) (13).
Southern blot analysis showed that the SHR strain is
missing the Cd36 bands present in both the BN progenitor
strain and the SHR-chr.4 congenic strain (Figure 2). South-
ern blot analysis of DNA from the stroke-prone SHR strain
revealed a pattern distinctly different from that observed in
the SHR progenitor strain (Figure 2). Analysis of the HinfI
RFLP described by Aitman et al. (13) also confirmed that
the stroke-prone SHR strain did not inherit the deletion
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Figure 2
Southern blot analysis of Cd36. The
Cd36 deletion variant is present in the
SHR strain (note missing bands in
lane 1) but not in the BN (lane 2),
SHR.BN-Il6/Npy congenic (lane 3),
or stroke-prone SHR (lane 4) strains.
Table 1
Serum levels of  glucose, insulin, and lipids in rats fed a high-fructose diet
Strain Glucose Insulin Cholesterol HDL Triglycerides Free fatty acids
mmol/L ng/mL mmol/L mmol/L mmol/L mmol/L
SHR 7.42 ± 0.20 0.78 ± 0.07 1.59 ± 0.07 1.13 ± 0.02 2.60 ± 0.28 315 ± 33
SHR.BN-Il6/Npy 7.62 ± 0.20 0.33 ± 0.03A 1.78 ± 0.05 1.15 ± 0.05 1.88 ± 0.17A 205 ± 21A
ASignificant difference between the SHR progenitor strain and SHR.BN-Il6/Npy congenic strain by t test (P < 0.05).
variant of Cd36 carried by the SHR (data not shown). In
contrast, SHR obtained from 3 different sources (Charles
River Laboratories, Taconic Farms, and the Czech Academy
of Sciences) were found to harbor the Cd36 deletion variant
reported by Aitman et al. (data not shown).
Hemodynamic analysis. The weekly daytime and night-
time systolic blood pressures in the SHR progenitor and
SHR-chr. 4 congenic strain are shown in Figure 3a. Both
daytime and nighttime systolic blood pressures were sig-
nificantly lower in the SHR congenic strain than in the
progenitor strain. The least square means for daytime
systolic blood pressures in the SHR progenitor strain
and SHR congenic strain were 170 – 4 mmHg vs. 157 –
3 mmHg, respectively (P < 0.025); and for nighttime sys-
tolic blood pressures, 173 – 3 vs. 159 – 3, respectively (P
< 0.005). Diastolic and mean blood pressures were also
lower in the congenic strain than in the progenitor
strain, but the differences were not statistically signifi-
cant (data not shown). Heart rates were similar between
the SHR progenitor and congenic strains, despite the
clear differences in systolic pressure (Figure 3b). The
growth rates of the SHR congenic and progenitor strains
were similar, although the mean body weight of the con-
genic strain tended to be slightly lower than that of the
progenitor strain (Figure 4). However, after the first week
of blood pressure measurements, the differences in body
weight did not achieve statistical significance. Thus, the
persistent differences in blood pressure between the SHR
progenitor and congenic strains cannot be readily attrib-
uted to any major strain differences in body weights. The
magnitude of the difference in blood pressure between
the SHR progenitor strain and SHR congenic strain was
not affected by fructose feeding (data not shown).
Risk-factor phenotyping. Circulating levels of glucose,
insulin, and lipids were similar between SHR progenitor
rats and SHR-chr.4 congenic rats fed standard laborato-
ry chow (data not shown). However, in SHR progenitor
rats fed the high-fructose diet, serum insulin, triglyc-
eride, and free fatty acid levels were much greater than in
SHR congenic rats fed the high-fructose diet (Table 1).
Serum glucose values were similar between the 2 groups
fed the high-fructose diet. Figure 5 shows the ratios of
serum insulin/glucose in SHR and SHR-chr.4 congenic
rats before and after administration of the high-fructose
diet. After fructose feeding, the insulin/glucose ratios
were significantly increased (P < 0.001) in the SHR pro-
genitor strain compared with the SHR-chr.4 congenic
strain, owing to the marked hyperinsulinemia in the
SHR progenitor strain. These metabolic changes were
also accompanied by marked impairment in glucose tol-
erance in the SHR progenitor strain. Figure 6 shows the
results of intraperitoneal glucose tolerance testing in the
SHR progenitor and SHR-chr.4 congenic strain. Baseline
glucose levels were similar in the 2 strains; however, after
glucose loading, marked and prolonged hyperglycemia
occurred in the SHR progenitor strain but not in the
SHR-chr.4 congenic strain.
Discussion
Glucose intolerance and hypertriglyceridemia are meta-
bolic risk factors for cardiovascular disease and are
often found in patients with essential hypertension (1,
2, 5). Evidence for disordered carbohydrate and lipid
metabolism has also been reported in the SHR model
of essential hypertension (4, 5, 9, 11). Despite extensive
research, the basis for this clustering of cardiovascular
risk factors remains a mystery. In a novel congenic
strain of SHR, we have found that transfer of a single
segment of chromosome 4 from the normotensive BN
rat onto the SHR background can induce significant
reductions in systolic blood pressure and ameliorate
fructose-induced glucose intolerance, hyperinsuline-
mia, and hypertriglyceridemia. These findings demon-
strate that a single chromosome region has the capaci-
ty to influence genetically a broad spectrum of systemic
cardiovascular risk factors involved in the hypertension
metabolic syndrome. The findings are consistent with
the hypothesis that a set of linked genes, or perhaps
even a single gene, on chromosome 4 can contribute to
the clustering of hypertension and multiple metabolic
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Figure 3
Blood pressures and heart rates. Daytime and nighttime average systolic
blood pressures (a) and heart rates (b) determined by radiotelemetry
over a period of 4 weeks in the SHR progenitor strain and the SHR.BN-
Il6/Npy congenic strain. Each data point represents the weekly daytime
(open symbols) or nighttime (filled symbols) average blood pressure or
heart rate (mean – SEM) in the SHR progenitor strain (circles; n = 7) and
the SHR.BN-Il6/Npy congenic strain (squares; n = 7). The sawtooth pat-
tern reflects the circadian variation in blood pressure and heart rate. Sys-
tolic blood pressure was significantly lower in the SHR congenic strain
than in the SHR progenitor strain during all daytime and nighttime peri-
ods. Heart rates were not significantly different between the 2 strains.
risk factors for atherosclerotic cardiovascular disease.
Recent studies have established that a deletion in the
Cd36 gene underlies defects in insulin sensitivity and cat-
echolamine-stimulated lipolysis in isolated adipocytes
from the SHR (13). Cd36 maps within the differential
segment of the SHR-chr. 4 congenic strain and encodes a
fatty acid receptor/transporter involved in the trans-
membrane transport of long-chain fatty acids. Trans-
genic overexpression of Cd36 has also been shown to
induce decreases in circulating levels of triglycerides and
fatty acids in FVB mice, although the effects of Cd36
overexpression on blood pressure and insulin sensitivity
remain to be determined (13). The observations in SHR
adipocytes and Cd36 transgenic mice, together with the
current results in the SHR-chr. 4 congenic strain, strong-
ly suggest that the SHR defect in Cd36 not only promotes
disordered carbohydrate and lipid metabolism at the cel-
lular level but also predisposes to systemic glucose intol-
erance, hyperinsulinemia, and hypertriglyceridemia. It is
possible that the alterations in systemic glucose tolerance
might involve mechanisms other than just insulin resist-
ance per se, e.g., alterations in gluconeogenesis, tissue glu-
cose delivery, etc. However, the previous studies in isolat-
ed SHR adipocytes strongly suggest that resistance to
insulin-stimulated glucose uptake and alterations in cel-
lular fatty acid metabolism might play at least some role
in the pathogenesis of impaired glucose tolerance in this
model (13). Abnormalities in lipid metabolism have been
proposed to contribute to impaired insulin sensitivity
and the pathogenesis of insulin-resistance disorders such
as non–insulin-dependent diabetes (20). In the SHR, fur-
ther studies will be required to determine whether the
alterations in fatty acid and triglyceride metabolism
induced by mutant Cd36 contribute to the pathogenesis
of systemic glucose intolerance by promoting insulin
resistance in skeletal muscle.
In the current studies, we have found that the capacity
of chromosome 4 to influence metabolic risk factors for
cardiovascular disease in the SHR is environmentally
determined. Circulating levels of glucose, insulin, triglyc-
erides, and fatty acids determined on single serum sam-
ples obtained during the day were similar between the
SHR progenitor and congenic strains fed standard labo-
ratory chow. In contrast, marked differences in glucose
tolerance and circulating levels of insulin, triglycerides,
and fatty acids were observed between SHR progenitor
and congenic rats fed a high-fructose diet. These obser-
vations are consistent with a role for environment-geno-
type interaction in determining cardiovascular risk, and
suggest that Cd36 deficiency can influence susceptibility
to dietary-induced exacerbation of common risk factors
for atherosclerotic heart disease. Given that Cd36 may
serve as a receptor for HDL, LDL, and VLDL, it will be of
interest to determine whether changes in the dietary
intake of fat can also exert different effects on systemic
cardiovascular risk factors in the SHR progenitor strain
versus the SHR-chr. 4 congenic strain (21).
Based on the differences in blood pressure between the
SHR progenitor and SHR congenic strains, it appears
that the segment of chromosome 4 trapped in the
SHR.BN-Il6/Npy strain may account for 15–20% of the
systolic hypertension in the SHR-BN model. This effect
is comparable to the effects of other blood pressure
QTLs mapped in the SHR either by linkage analysis or
by chromosome transfer studies in congenic strains (16,
22–26). Because multiple genes are involved in the
pathogenesis of increased blood pressure in the SHR, the
effect of this single chromosome region on systolic
blood pressure is relatively substantial. A number of
interesting candidate genes for hypertension are linked
to Cd36 within the differential chromosome segment of
the SHR congenic strain that includes the genes for
endothelial nitric oxide synthase, leptin, and neuropep-
tide Y. By subdividing the target segment of chromo-
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Figure 4
Body weights. Mean body weights in the SHR progenitor strain (filled cir-
cles) and the SHR.BN-Il6/Npy congenic strain (open circles) determined
over the 4-week period of blood pressure measurement. Mean body
weight of the SHR progenitor strain was significantly lower than that of
the SHR congenic strain at 11 weeks of age (*P < 0.05).
Figure 5
Insulin/glucose ratios. Scatter plot showing serum insulin/glucose ratios
in SHR progenitor rats (filled symbols; n = 9) and SHR.BN-Il6/Npy con-
genic rats (open symbols; n = 6) before and after 15 days on a high-fruc-
tose diet. Horizontal bars denote group means. After fructose feeding,
insulin/glucose ratios were significantly greater in the SHR progenitor
strain than in the SHR congenic strain (*P < 0.001).
some 4 in multiple congenic sublines, it will be possible
to test whether the clustering of metabolic risk factors
with increased blood pressure depends on linkage
between Cd36 and other genes trapped within the dif-
ferential segment of the SHR congenic strain.
Although Cd36 deficiency appears to be a likely deter-
minant of disordered carbohydrate and lipid metabolism
in the SHR, the role of defective Cd36 in the pathogene-
sis of spontaneous hypertension is a far more open ques-
tion. In demonstrating that the SHR congenic strain has
significantly lower blood pressure than the SHR progen-
itor strain, we have clearly established that the transferred
segment of chromosome 4 is involved in the genetic con-
trol of hypertension in the SHR-BN model. However, in
the absence of supporting studies of the hemodynamic
effects of Cd36 in transgenic or knockout animals, it is
premature to conclude that the SHR deletion in Cd36
contributes to the effects of this region of chromosome 4
on the pathogenesis of hypertension.
In the current studies, we have found that SHR from
several different colonies carry the deletion variant in
Cd36. However, genotype testing using Southern blot
analysis indicates that the stroke-prone strain of SHR
did not inherit the SHR deletion variant of Cd36. This
finding might suggest that Cd36 itself is not the blood
pressure QTL trapped in the differential segment of the
SHR-chr. 4 congenic strain. According to reports describ-
ing the derivation of the SHR and the stroke-prone SHR
strains, the hypertension in the original SHR line was
largely fixed by the F5 generation of selective inbreeding
(27). However, the stroke-prone subline did not branch
off from the original SHR line until after the F10 gener-
ation (28). Had the SHR deletion variant in Cd36 been
important in the genetic evolution of hypertension in
the SHR, it would have been fixed during the initial
process of selective inbreeding for hypertension, which
was essentially complete by the F5 generation, i.e., before
splitting off of the stroke-prone subline. If so, the stroke-
prone SHR subline would have inherited the deletion
variant in Cd36 from the SHR. However, the fact that the
stroke-prone SHR did not inherit the SHR deletion vari-
ant of Cd36 suggests that this gene was not particularly
important in the original process of selection for hyper-
tension in the SHR. Of course, the subsequent inbreed-
ing of the SHR over multiple generations may have
resulted in the fixation of additional genes (e.g., the
Cd36 deletion variant) that further increased blood pres-
sure in the SHR strain. That the stroke-prone SHR did
not inherit the SHR deletion variant does not exclude
the possibility that Cd36 deficiency might contribute to
hypertension at some level. Nevertheless, the current
findings, together with the published genealogy of the
SHR and stroke-prone SHR strains, appear to indicate
that the deletion in Cd36 did not play a key role in the
selection for increased blood pressure that occurred dur-
ing the early derivation of the SHR.
Recently, Furukawa et al. (12) reported that SHR
(SHR/Izm) obtained from a commercial supplier in
Izumo, Japan, displayed insulin resistance when com-
pared with WKY rats (WKY/Izm) obtained from the
same source. In contrast, SHR (SHR/NCrj) obtained
from a commercial source in Tokyo did not show evi-
dence of insulin resistance when compared with WKY
rats (WKY/NCrj) obtained from the Tokyo source (12).
That SHRs from both Izumo and Tokyo exhibit hyper-
tension, whereas only SHRs from Izumo exhibit insulin
resistance, suggests that spontaneous hypertension per
se is not inextricably related to a genetic predisposition
to insulin resistance. Although we have found evidence
of Cd36 deletions in SHRs from 3 different sources, it is
possible that other colonies of SHRs exist that do not
harbor deletions in Cd36. Given the well-known genetic
heterogeneity among normotensive WKY rats from dif-
ferent sources, it is also conceivable that some WKY sub-
lines exist that carry deletions in Cd36 (29). It remains to
be determined whether genetic variation in insulin sen-
sitivity among SHRs from different sources is related to
genetic variation in Cd36.
In a novel SHR congenic strain, we have succeeded in
isolating a single chromosome region that is involved in
the genetic regulation of multiple cardiovascular risk
factors, including glucose intolerance, hypertriglyc-
eridemia, and hypertension. This chromosome region
includes the SHR deletion variant in Cd36 responsible
for defective carbohydrate and lipid metabolism in iso-
lated adipocytes. Given these observations, it will be of
interest to determine whether genetic variants in Cd36
are associated with clustering of metabolic cardiovascu-
lar risk factors in humans. It may also be of interest to
determine whether genes linked to Cd36 on human
chromosome 7q are involved in the pathogenesis of
human essential hypertension. Finally, the current
results indicate that genetic dissection techniques in
congenic strains can provide a powerful approach for
investigating the basis for risk factor clustering in spon-
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Figure 6
Glucose tolerance testing. Glucose tolerance test results in the SHR pro-
genitor strain (circles; n = 9) and the SHR.BN-Il6/Npy congenic strain
(squares; n = 6). Serum glucose levels were significantly greater in the SHR
progenitor strain than in the SHR congenic strain at 30, 60, and 120 min-
utes after glucose loading (*P < 0.05).
taneous hypertension. These findings should also serve
to motivate the development of congenic sublines and
knockout models to investigate further the relationship
of defective Cd36 to the clustering of systemic cardio-
vascular risk factors and the pathogenesis of sponta-
neous hypertension.
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